The Use of L-carnitine in Modulating Pain and Inflammation in Rheumatoid Arthritis Patients

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

This study aims at evaluating the possible efficacy and safety of L-carnitine in rheumatoid arthritis via targeting Jak/STAT pathway and TGF-β1

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

• Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 criteria (9) i.e., 28 joints disease activity score (DAS-28) \>2.6.

• Patients receive the conventional DMARDs

• Both sexes.

• Age range between 18 and 70 years old.

Locations
Other Locations
Egypt
Tanta university
RECRUITING
Tanta
Contact Information
Primary
Abdallah A Eldisouky
PG_165476@pharm.tanta.edu.eg
201279142631
Time Frame
Start Date: 2023-03-05
Estimated Completion Date: 2026-03-05
Participants
Target number of participants: 46
Treatments
No_intervention: control group
this group will include 23 patients which will receive the traditional therapy of RA for 3 months.
Active_comparator: L-carnitine group
this group will include 23 patients which will receive 500mg L-carnitine two times daily after meal plus the traditional therapy of RA for 3 months.
Related Therapeutic Areas
Sponsors
Leads: Tanta University

This content was sourced from clinicaltrials.gov